
    
      In the perspective of future therapeutic interventions, which could involve protein, cellular
      and/or gene therapy, it is essential to investigate RDEB patients with regards to their
      immune tolerance to type VII collagen and their capacity of their cells for tissue
      reconstruction.
    
  